PTGS2 and neoplasm: The selective cyclooxygenase 2 (COX-2) inhibitor celecoxib blocks the formation of Cox-2-mediated, cancer-stimulating AA metabolites and has demonstrated promising preclinical and clinical anti-tumor activity in a variety of human tumors, including pancreatic cancer [23]–[25].